Is melatonin associated with pro-inflammatory cytokine activity and liver fibrosis in non-alcoholic fatty liver disease (NAFLD) patients?

Aim: The associations between serum levels of melatonin and concentrations of tumor necrosis factor (TNF)-a and interleukin (IL)-6 were assessed among patients with different degrees of non-alcoholic fatty liver disease. Background: Non-alcoholic fatty liver disease (NAFLD) has become a very common worldwide disease. Methods: In this cross-sectional study, adult patients diagnosed with fatty liver disease by Fibroscan evaluation were included if they met the inclusion/exclusion criteria for NAFLD. The participants were categorized into the three following groups: 1) fibrosis> 9.1KP and steatosis >290 dbm; 2) fibrosis: 6-9.0 KP and steatosis 240-285; and 3) fibrosis < 5.8 KP and steatosis<240 dbm. Post-fasting, 5 ml of venous blood was collected for laboratory assessment, and a questionnaire including demographic, anthropometric, laboratories and clinical data was completed. Results: A total of 97 participants were included. The mean age was 42.21±11 years, and 59 patients (60.0%) were female. Melatonin levels as well as pro-inflammatory cytokines levels were correlated with advancing fibrosis and steatosis in univariate analysis. A significant association was observed between these cytokines and advancing fibrosis, severe steatosis levels, and melatonin concentrations. Furthermore, in the multiple linear regression model, melatonin levels showed a significant association with these cytokines. Conclusion: Melatonin may have protective effects on tissue injury during advancing liver fibrosis via cytokines modulation. Therefore, it can be considered as a potential therapeutic management strategy for NAFLD.

[1]  J. Gordon,et al.  Mechanisms of muscle insulin resistance and the cross‐talk with liver and adipose tissue , 2020, Physiological reports.

[2]  G. Kaltsakas,et al.  Sleep disorder in patients with chronic liver disease: a narrative review , 2020, Journal of thoracic disease.

[3]  Lanjuan Li,et al.  Protective role of melatonin in early‐stage and end‐stage liver cirrhosis , 2019, Journal of cellular and molecular medicine.

[4]  R. Rezzani,et al.  Melatonin Effects on Non-Alcoholic Fatty Liver Disease Are Related to MicroRNA-34a-5p/Sirt1 Axis and Autophagy , 2019, Cells.

[5]  S. Piro,et al.  Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview , 2019, International journal of molecular sciences.

[6]  Jing Zhang,et al.  Melatonin suppresses TLR9-triggered proinflammatory cytokine production in macrophages by inhibiting ERK1/2 and AKT activation , 2018, Scientific Reports.

[7]  F. Bessone,et al.  Molecular pathways of nonalcoholic fatty liver disease development and progression , 2018, Cellular and Molecular Life Sciences.

[8]  G. Ortiz,et al.  Efficacy of Melatonin on Serum Pro-inflammatory Cytokines and Oxidative Stress Markers in Relapsing Remitting Multiple Sclerosis. , 2018, Archives of medical research.

[9]  Ariel D. Quiroga,et al.  Disruption of tumor necrosis factor alpha receptor 1 signaling accelerates NAFLD progression in mice upon a high-fat diet. , 2018, Journal of Nutritional Biochemistry.

[10]  B. Neuschwander‐Tetri,et al.  Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.

[11]  M. Kampa,et al.  Activin-A causes Hepatic stellate cell activation via the induction of TNFα and TGFβ in Kupffer cells. , 2018, Biochimica et biophysica acta. Molecular basis of disease.

[12]  C. Alves,et al.  Inflammatory cytokines and non-alcoholic fatty liver disease (NAFLD) in obese children and adolescents. , 2018, Nutricion hospitalaria.

[13]  V. Wong,et al.  Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. , 2017, Journal of hepatology.

[14]  C. Isarankura-Na-Ayudhya,et al.  High-fat diet-induced plasma protein and liver changes in obese rats can be attenuated by melatonin supplementation. , 2017, Nutrition research.

[15]  Yonggong Zhai,et al.  Melatonin prevents obesity through modulation of gut microbiota in mice , 2017, Journal of pineal research.

[16]  M. Ahmadian,et al.  The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial , 2017, Advanced biomedical research.

[17]  Yue Zhou,et al.  Melatonin for the prevention and treatment of cancer , 2017, Oncotarget.

[18]  F. Nevens,et al.  Pro-Inflammatory Cytokines but Not Endotoxin-Related Parameters Associate with Disease Severity in Patients with NAFLD , 2016, PloS one.

[19]  M. Akash,et al.  Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? , 2016, Journal of Biomedical Science.

[20]  R. Reiter,et al.  Melatonin as an antioxidant: under promises but over delivers , 2016, Journal of pineal research.

[21]  F. Pavón,et al.  Chronic IL-6 Administration Desensitizes IL-6 Response in Liver, Causes Hyperleptinemia and Aggravates Steatosis in Diet-Induced-Obese Mice , 2016, PloS one.

[22]  Yujing Chi,et al.  Role of intrahepatic B cells in non‐alcoholic fatty liver disease by secreting pro‐inflammatory cytokines and regulating intrahepatic T cells , 2016, Journal of digestive diseases.

[23]  R. Reiter,et al.  Melatonin's role in preventing toxin-related and sepsis-mediated hepatic damage: A review. , 2016, Pharmacological research.

[24]  B. Staels,et al.  Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. , 2016, Annual review of physiology.

[25]  S. Emir,et al.  The effects of melatonin on liver functions in arsenic-induced liver damage. , 2016, Ulusal cerrahi dergisi.

[26]  K. Faber,et al.  Melatonin suppresses activation of hepatic stellate cells through RORα‐mediated inhibition of 5‐lipoxygenase , 2015, Journal of pineal research.

[27]  C. McClain,et al.  Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. , 2015, Clinical biochemistry.

[28]  F. Nevens,et al.  Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[29]  W. Abdo,et al.  Melatonin reduces hepatic mitochondrial dysfunction in diabetic obese rats , 2015, Journal of pineal research.

[30]  F. Pavón,et al.  Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice , 2015, Disease Models & Mechanisms.

[31]  D. Skene,et al.  Sleep and Circadian Rhythms in Hospitalized Patients with Decompensated Cirrhosis: Effect of Light Therapy , 2015, Neurochemical Research.

[32]  S. Das,et al.  Role of Cytokines in the Pathogenesis of Non-Alcoholic Fatty Liver Disease , 2011, Indian Journal of Clinical Biochemistry.

[33]  F. Verdam,et al.  Novel Evidence for Chronic Exposure to Endotoxin in Human Nonalcoholic Steatohepatitis , 2011, Journal of clinical gastroenterology.

[34]  Wei Wei,et al.  Regulatory Effect of Melatonin on Cytokine Disturbances in the Pristane-Induced Lupus Mice , 2010, Mediators of inflammation.

[35]  G. Bedogni,et al.  Epidemiology of Non-Alcoholic Fatty Liver Disease , 2010, Digestive Diseases.

[36]  G. El-Sokkary,et al.  Melatonin administration ameliorates cadmium-induced oxidative stress and morphological changes in the liver of rat. , 2010, Ecotoxicology and environmental safety.

[37]  Patrice D Cani,et al.  Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. , 2009, Current opinion in pharmacology.

[38]  D. Cardinali,et al.  Therapeutic Actions of Melatonin in Cancer: Possible Mechanisms , 2008, Integrative cancer therapies.

[39]  D. Tobin,et al.  Melatonin in the skin: synthesis, metabolism and functions , 2008, Trends in Endocrinology & Metabolism.

[40]  Rabih Bechara,et al.  Cytokines and alcohol. , 2006, Alcoholism, clinical and experimental research.

[41]  A. Moser,et al.  Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease , 2003, Hepatology.